News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Vectura Group plc Positive Interim Results for Parkinson’s Disease Drug
October 31, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON - Vectura Group has announced positive results for an interim study of its VR040 drug, a product designed to treat periods of complete or partial immobility in patients with Parkinson's disease.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Europe
MORE ON THIS TOPIC
Obesity
Lilly’s Amylin Agonist Headed to Phase III After Eliciting up to 20% Weight Loss
November 6, 2025
·
3 min read
·
Heather McKenzie
IN PARTNERSHIP WITH PII
Thoughtful Tech: How Removing Technological Burdens Can Improve Clinical Trial Compliance and Patient Experience
November 6, 2025
·
1 min read
·
BioSpace Insights
Business
Basel Life Sciences Scene Embraces International Companies, Startups
November 6, 2025
·
6 min read
·
Angela Gabriel
FDA
Webinar: FDA in 2025: Navigating an Uncertain Regulatory Future
November 5, 2025
·
1 min read
·
Jef Akst
